Overview

Chidamide and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to explore and evaluate the efficacy of Chidamide combined with metronomic capecitabine in the treatment of metastatic triple-negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

wang shusen

Treatments:

Capecitabine